Capital One Financial Brokers Raise Earnings Estimates for Immunocore Holdings plc (NASDAQ:IMCR)

Immunocore Holdings plc (NASDAQ:IMCR) – Equities researchers at Capital One Financial raised their FY2028 EPS estimates for shares of Immunocore in a research report issued on Thursday, May 2nd. Capital One Financial analyst N. Quibria now anticipates that the company will post earnings per share of $1.85 for the year, up from their prior forecast of $1.66. The consensus estimate for Immunocore’s current full-year earnings is ($1.55) per share.

Other research analysts have also recently issued research reports about the stock. SVB Leerink began coverage on shares of Immunocore in a research report on Monday, April 29th. They set an “outperform” rating and a $74.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research note on Thursday, April 11th. Leerink Partnrs reiterated an “outperform” rating on shares of Immunocore in a report on Monday, April 29th. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Immunocore in a report on Wednesday, March 6th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.92.

Immunocore Stock Performance

NASDAQ IMCR opened at $61.91 on Monday. The company has a market cap of $3.08 billion, a P/E ratio of -53.37 and a beta of 0.92. The business’s 50 day moving average price is $61.28 and its 200-day moving average price is $61.14. Immunocore has a fifty-two week low of $42.21 and a fifty-two week high of $76.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.77 and a current ratio of 3.80.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The company had revenue of $70.16 million during the quarter, compared to analysts’ expectations of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company’s revenue was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.63) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. FORA Capital LLC purchased a new stake in shares of Immunocore in the 1st quarter worth approximately $777,000. Capstone Investment Advisors LLC purchased a new stake in shares of Immunocore during the 1st quarter worth $1,227,000. Principal Financial Group Inc. boosted its position in Immunocore by 7.0% during the first quarter. Principal Financial Group Inc. now owns 517,204 shares of the company’s stock valued at $33,618,000 after purchasing an additional 33,868 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 69.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after purchasing an additional 2,721 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Immunocore by 2.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company’s stock valued at $5,695,000 after buying an additional 1,830 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.